Published in Mol Endocrinol on October 01, 1991
A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res (2009) 6.15
The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res (1994) 3.52
Nuclear localization signals overlap DNA- or RNA-binding domains in nucleic acid-binding proteins. Nucleic Acids Res (1995) 2.52
Splinkerettes--improved vectorettes for greater efficiency in PCR walking. Nucleic Acids Res (1995) 2.51
A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate (2011) 2.21
Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clin Cancer Res (2014) 2.10
The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. Mol Cell Biol (1999) 2.00
Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins. Mol Cell Biol (1999) 1.93
Androgen receptor signaling in prostate cancer development and progression. J Carcinog (2011) 1.90
Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity. Cancer Res (2011) 1.77
The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription. Mol Cell Biol (1999) 1.70
AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR. Mol Cell Biol (2003) 1.68
Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor. Mol Pharmacol (2003) 1.65
An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest (2013) 1.64
Identification of a novel RING finger protein as a coregulator in steroid receptor-mediated gene transcription. Mol Cell Biol (1998) 1.60
Nuclear import of the human androgen receptor. Biochem J (1993) 1.58
Hey1, a mediator of notch signaling, is an androgen receptor corepressor. Mol Cell Biol (2005) 1.42
Modulation of transcriptional activation and coactivator interaction by a splicing variation in the F domain of nuclear receptor hepatocyte nuclear factor 4alpha1. Mol Cell Biol (1999) 1.40
Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene (2014) 1.31
Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci U S A (1992) 1.28
Androgen receptor decoy molecules block the growth of prostate cancer. Proc Natl Acad Sci U S A (2007) 1.27
A new trick of an old molecule: androgen receptor splice variants taking the stage?! Int J Biol Sci (2011) 1.27
Negative modulation of androgen receptor transcriptional activity by Daxx. Mol Cell Biol (2004) 1.26
Androgen receptor antagonists in castration-resistant prostate cancer. Cancer J (2013) 1.19
FoxO1 mediates PTEN suppression of androgen receptor N- and C-terminal interactions and coactivator recruitment. Mol Endocrinol (2008) 1.17
Cyclin D3/CDK11p58 complex is involved in the repression of androgen receptor. Mol Cell Biol (2007) 1.16
Posttranslational modification of the androgen receptor in prostate cancer. Int J Mol Sci (2013) 1.16
Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity. Protein Sci (2006) 1.15
Interaction of the human androgen receptor transactivation function with the general transcription factor TFIIF. Proc Natl Acad Sci U S A (1997) 1.14
Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells. Proc Natl Acad Sci U S A (2005) 1.14
Identification and characterization of ART-27, a novel coactivator for the androgen receptor N terminus. Mol Biol Cell (2002) 1.11
Androgen receptor and its splice variants in prostate cancer. Cell Mol Life Sci (2011) 1.11
Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signal (2008) 1.11
Estrogen receptor transcription and transactivation: Structure-function relationship in DNA- and ligand-binding domains of estrogen receptors. Breast Cancer Res (2000) 1.01
Decoding the androgen receptor splice variants. Transl Androl Urol (2013) 1.01
Two mutations in the hormone binding domain of the vitamin D receptor cause tissue resistance to 1,25 dihydroxyvitamin D3. J Clin Invest (1993) 1.00
Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer. Expert Rev Endocrinol Metab (2010) 1.00
Delineation of a small region within the major transactivation domain of the human glucocorticoid receptor that mediates transactivation of gene expression. Proc Natl Acad Sci U S A (1994) 0.99
Phenotypic diversity in siblings with partial androgen insensitivity syndrome. Arch Dis Child (1997) 0.97
ERK regulates calpain 2-induced androgen receptor proteolysis in CWR22 relapsed prostate tumor cell lines. J Biol Chem (2009) 0.96
The androgen receptor gene mutations database. Nucleic Acids Res (1994) 0.94
Complete testicular feminization caused by an amino-terminal truncation of the androgen receptor with downstream initiation. J Clin Invest (1993) 0.94
Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer. J Biol Chem (2014) 0.93
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. Genome Biol (2016) 0.93
Differential splicing of human androgen receptor pre-mRNA in X-linked Reifenstein syndrome, because of a deletion involving a putative branch site. Am J Hum Genet (1994) 0.91
Molecular genetics of human androgen insensitivity. Eur J Pediatr (1993) 0.90
Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions. Curr Oncol (2012) 0.89
Repression of androgen receptor activity by HEYL, a third member of the Hairy/Enhancer-of-split-related family of Notch effectors. J Biol Chem (2011) 0.88
Calmodulin protects androgen receptor from calpain-mediated breakdown in prostate cancer cells. J Cell Physiol (2011) 0.88
Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer. Oncotarget (2015) 0.87
Androgen receptor gene mutation, rearrangement, polymorphism. Transl Androl Urol (2013) 0.87
Human androgen receptor expressed in HeLa cells activates transcription in vitro. Nucleic Acids Res (1994) 0.87
Localization and hormonal stimulation of phosphorylation sites in the LNCaP-cell androgen receptor. Biochem J (1993) 0.87
Targeting alternative sites on the androgen receptor to treat castration-resistant prostate cancer. Int J Mol Sci (2013) 0.86
DAX-1 expression in human breast cancer: comparison with estrogen receptors ER-alpha, ER-beta and androgen receptor status. Breast Cancer Res (2004) 0.85
Kinetic and thermodynamic characterization of dihydrotestosterone-induced conformational perturbations in androgen receptor ligand-binding domain. Mol Endocrinol (2009) 0.85
Role of the HSP90-associated cochaperone p23 in enhancing activity of the androgen receptor and significance for prostate cancer. Mol Endocrinol (2012) 0.85
Related individuals with different androgen receptor gene deletions. J Clin Invest (1993) 0.84
Constitutive activity of the androgen receptor. Adv Pharmacol (2014) 0.84
Characterization of niphatenones that inhibit androgen receptor N-terminal domain. PLoS One (2014) 0.82
Two panels of steroid receptor luciferase reporter cell lines for compound profiling. Comb Chem High Throughput Screen (2011) 0.81
The N-terminal domain of the androgen receptor drives its nuclear localization in castration-resistant prostate cancer cells. J Steroid Biochem Mol Biol (2014) 0.80
Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer. Oncologist (2016) 0.80
AR-Q640X, a model to study the effects of constitutively active C-terminally truncated AR variants in prostate cancer cells. World J Urol (2012) 0.80
In vitro translation of androgen receptor cRNA results in an activated androgen receptor protein. Biochem J (1993) 0.80
Androgen receptor signalling in prostate cancer: the functional consequences of acetylation. J Biomed Biotechnol (2010) 0.80
Stilbene induced inhibition of androgen receptor dimerization: implications for AR and ARΔLBD-signalling in human prostate cancer cells. PLoS One (2014) 0.80
Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy. CNS Neurol Disord Drug Targets (2013) 0.80
Structure-based virtual screening and identification of a novel androgen receptor antagonist. J Biol Chem (2012) 0.80
Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications. Clin Cancer Res (2014) 0.79
Characterization of 2-amino-1-methyl-6-phenylimidazo[4,5b]pyridine at androgen receptor: mechanistic support for its role in prostate cancer. Am J Cancer Res (2014) 0.79
Targeting androgen receptor and JunD interaction for prevention of prostate cancer progression. Prostate (2014) 0.79
Phenotypic variation and detection of carrier status in the partial androgen insensitivity syndrome. Arch Dis Child (1993) 0.78
On the origins of the androgen receptor low molecular weight species. Horm Cancer (2013) 0.78
Genome-Wide Association Studies for Comb Traits in Chickens. PLoS One (2016) 0.78
An imaging agent to detect androgen receptor and its active splice variants in prostate cancer. JCI Insight (2016) 0.77
Sintokamide A Is a Novel Antagonist of Androgen Receptor That Uniquely Binds Activation Function-1 in Its Amino-terminal Domain. J Biol Chem (2016) 0.77
Mutations of the androgen receptor gene identified in perineal hypospadias. J Med Genet (1993) 0.76
Engineered repressors are potent inhibitors of androgen receptor activity. Oncotarget (2014) 0.76
Splice Variants of Androgen Receptor and Prostate Cancer. Oncol Rev (2016) 0.75
Mutation of androgen receptor N-terminal phosphorylation site Tyr-267 leads to inhibition of nuclear translocation and DNA binding. PLoS One (2015) 0.75
Targeting of Androgen Receptor Expression by Andro-miRs as Novel Adjunctive Therapeutics in Prostate Cancer. J Cancer Ther (2013) 0.75
A Tale of Two Signals: AR and WNT in Development and Tumorigenesis of Prostate and Mammary Gland. Cancers (Basel) (2017) 0.75
Bypassing drug-resistance mechanisms of prostate cancer with small-molecules that target androgen receptor chromatin interactions. Mol Cancer Ther (2017) 0.75
A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun (1990) 3.79
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res (1994) 3.43
Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res (1997) 3.37
A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab (1998) 2.45
Ribosomal precursor particles from yeast. Exp Cell Res (1975) 2.41
Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol (2007) 2.26
The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol (1992) 2.21
Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res (1998) 2.10
Expression of E-cadherin, alpha- & beta-catenin, and CD44V6 and the subcellular localization of E-cadherin and CD44V6 in normal epidermis and basal cell carcinoma. Hum Pathol (1999) 2.06
Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem (1996) 2.05
Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J Biol Chem (1995) 2.02
Targeted disruption of the Insl3 gene causes bilateral cryptorchidism. Mol Endocrinol (1999) 1.99
Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol (1994) 1.94
The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res (2001) 1.86
An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol (1997) 1.85
Atypical adenomatous hyperplasia of the prostate: morphologic criteria for its distinction from well-differentiated carcinoma. Hum Pathol (1993) 1.82
Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer (1991) 1.81
Characterization of a zinc-finger protein and its association with apoptosis in prostate cancer cells. J Natl Cancer Inst (2000) 1.78
A novel gene which is up-regulated during colon epithelial cell differentiation and down-regulated in colorectal neoplasms. Lab Invest (1997) 1.74
Maturation of ribosomes in yeast. I Kinetic analysis by labelling of high molecular weight rRNA species. Biochim Biophys Acta (1976) 1.74
The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol (1991) 1.72
Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene (2011) 1.71
High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res (2001) 1.70
Mechanisms of androgen receptor activation and function. J Steroid Biochem Mol Biol (1999) 1.68
Lack of association between five polymorphisms in the human glucocorticoid receptor gene and glucocorticoid resistance. Hum Genet (1997) 1.66
Cloning, structure and expression of a cDNA encoding the human androgen receptor. Biochem Biophys Res Commun (1988) 1.64
Pathologic features of prostate cancer found at population-based screening with a four-year interval. J Natl Cancer Inst (2001) 1.63
Nuclear import of the human androgen receptor. Biochem J (1993) 1.58
Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam. Urology (2006) 1.51
Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam. J Natl Cancer Inst (2003) 1.46
Evidence for a protective role of interferon in resistance to murine cytomegalovirus and its control by non-H-2-linked genes. Infect Immun (1982) 1.44
Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry (1992) 1.44
The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion. J Pathol (2006) 1.40
Combinatorial association and abundance of components of interferon-stimulated gene factor 3 dictate the selectivity of interferon responses. Proc Natl Acad Sci U S A (1995) 1.40
The N-terminal domain of the human androgen receptor is encoded by one, large exon. Mol Cell Endocrinol (1989) 1.38
Trinucleotide repeat polymorphism in the androgen receptor gene (AR). Nucleic Acids Res (1992) 1.34
The interferon-stimulated gene 54 K promoter contains two adjacent functional interferon-stimulated response elements of different strength, which act synergistically for maximal interferon-alpha inducibility. Eur J Biochem (1994) 1.33
Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am J Pathol (1996) 1.29
Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2). Mol Endocrinol (1998) 1.26
Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor. Biochemistry (1997) 1.24
Epitope prediction and confirmation for the human androgen receptor: generation of monoclonal antibodies for multi-assay performance following the synthetic peptide strategy. Biochim Biophys Acta (1991) 1.24
Organization, structure and expression of murine interferon alpha genes. Nucleic Acids Res (1985) 1.24
Genotype versus phenotype in families with androgen insensitivity syndrome. J Clin Endocrinol Metab (2001) 1.22
Androgen receptor expression in human tissues: an immunohistochemical study. J Histochem Cytochem (1991) 1.20
Calcium oxalate nephrolithiasis: effect of renal crystal deposition on the cellular composition of the renal interstitium. Am J Kidney Dis (1999) 1.20
Structure, chromosome localization, and regulation of expression of the interferon-regulated mouse Ifi54/Ifi56 gene family. Genomics (1994) 1.19
Localization of androgen receptors in human skin by immunohistochemistry: implications for the hormonal regulation of hair growth, sebaceous glands and sweat glands. J Endocrinol (1992) 1.18
Detection of factor VIII/coagulant antigen in human liver tissue. Nature (1983) 1.16
The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol (1997) 1.16
17Beta-hydroxysteroid dehydrogenase-3 deficiency: diagnosis, phenotypic variability, population genetics, and worldwide distribution of ancient and de novo mutations. J Clin Endocrinol Metab (1999) 1.16
Variation of prostate-specific antigen expression in different tumour growth patterns present in prostatectomy specimens. Urol Res (1990) 1.14
Characterization of an expanded glutamine repeat androgen receptor in a neuronal cell culture system. Neurobiol Dis (1997) 1.13
A 6-kb promoter fragment mimics in transgenic mice the prostate-specific and androgen-regulated expression of the endogenous prostate-specific antigen gene in humans. Mol Endocrinol (1997) 1.12
Differentially expressed genes in androgen-dependent and -independent prostate carcinomas. Cancer Res (1997) 1.11
Aberrant splicing of androgen receptor mRNA results in synthesis of a nonfunctional receptor protein in a patient with androgen insensitivity. Proc Natl Acad Sci U S A (1990) 1.10
High-affinity binding of oestradiol-17beta by cytosols from testis interstitial tissue, pituitary, adrenal, liver and accessory sex glands of the male rat. Biochem J (1974) 1.09
Involvement of insulin-like factor 3 (Insl3) in diethylstilbestrol-induced cryptorchidism. Endocrinology (2000) 1.09
Transcriptional regulation of androgen receptor gene expression in Sertoli cells and other cell types. Mol Cell Endocrinol (1992) 1.08
Steroid hormone receptor phosphorylation: is there a physiological role? Mol Cell Endocrinol (1994) 1.08
Hormone-induced dissociation of the androgen receptor-heat-shock protein complex: use of a new monoclonal antibody to distinguish transformed from nontransformed receptors. Biochemistry (1992) 1.08
Domains of the human androgen receptor and glucocorticoid receptor involved in binding to the nuclear matrix. J Cell Biochem (1995) 1.07
Orthotopic implantation of human prostate cancer cell lines: a clinically relevant animal model for metastatic prostate cancer. Prostate (1997) 1.07
Immunolocalization of interleukin-4 in eosinophils in the bronchial mucosa of atopic asthmatics. Am J Respir Cell Mol Biol (1996) 1.07
The androgen receptor in prostate cancer. Pathol Res Pract (1996) 1.06
Detailed analysis of the ribosomal RNA synthesis in yeast. Biochim Biophys Acta (1975) 1.06
An exonic point mutation of the androgen receptor gene in a family with complete androgen insensitivity. Am J Hum Genet (1990) 1.06
Expression and copy number analysis of TRPS1, EIF3S3 and MYC genes in breast and prostate cancer. Br J Cancer (2004) 1.06
Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer. J Urol (2000) 1.05
Characterization of the prostate-specific antigen gene: a novel human kallikrein-like gene. Biochem Biophys Res Commun (1989) 1.05
Androgen receptor mutations. J Steroid Biochem Mol Biol (1995) 1.05
Molecular evolution of multiple recurrent cancers of the bladder. Hum Mol Genet (2000) 1.04
Two different, overlapping pathways of transcription initiation are active on the TATA-less human androgen receptor promoter. The role of Sp1. J Biol Chem (1993) 1.03
Characterization of the human androgen receptor transcription unit. J Biol Chem (1991) 1.03
An immunohistochemical evaluation of androgen and progesterone receptors in ovarian tumors. Hum Pathol (1993) 1.03